1) Luton JP, Cerdas S, Billaud L, et a1. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Eng1 J Med 1990 ; 322 : 1195.
2) Stojadinovic A, Ghossein RA, Hoos A, et a1. Adreno-cortical carcinoma : clinical, morphologic, and mo-lecular characterization. J Clin Onco12002 ; 20 : 941.
3) NIH state-of-the-science statement on manage-ment of the clinically inapparent adrenal mass ("incidentaloma") [editorial] . NIH Consens State Sci Statements 2002 ; 19 : 1.
4) Terzolo M, Angeli A, Fassnacht M, et a1. Adjuvant mitotane treatment for adrenocortical carcinoma.N Eng1 J Med 2007 ; 356 : 2372.
5) Bukowski RM, Wolfe M, Levine HS, et a1. Phase II trial of mitotane and cisplatin in patients with adre-na1 carcinoma:a Southwest Oncology Group study.J Clin Onco1 1993 ; 11 : 161.